NCT00571779
Withdrawn
Phase 2
Thoracoscopically-Assisted Epicardial Bilateral Pulmonary Vein Isolations Using the AtriCure Bipolar System and Exclusion of the Left Atrial Appendage for the Treatment of Atrial Fibrillation
ConditionsAtrial Fibrillation
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Atrial Fibrillation
- Sponsor
- AtriCure, Inc.
- Primary Endpoint
- Feasibility of performing the operation by demonstrating the ability to consistently isolate the left and right pulmonary veins and to confirm conduction block across the roof, anterior and LAA linear lesions.
- Status
- Withdrawn
- Last Updated
- 15 years ago
Overview
Brief Summary
Feasibility study arm to evaluate the safety of adding the left atrial linear connecting lesions of the Cox-Maze lesion set to the current RESTORE SR II IDE study procedure of performing pulmonary vein isolation, selected left atrial autonomic ganglionated plexi (GP) ablation, and optional left atrial appendage (LAA) excision/exclusion on a beating heart for patients with permanent or persistent Atrial Fibrillation (AF).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient between 18 and 80 years of age
- •Patient with documented symptomatic persistent or permanent AF and failure or intolerance of one or more Class I or Class III antiarrhythmic drugs.
- •Persistent AF: AF that is not self-terminating or is terminated electrically or pharmacologically.
- •Longstanding AF: Persistent AF of 12 months (or longer) duration.
- •Permanent AF: Longstanding AF in which electrical or pharmacological cardioversion has failed or has not been attempted.
- •Patient is willing and able to provide written informed consent.
- •Patient has a life expectancy of at least 2 years.
- •Patient is willing and able to attend the scheduled follow-up visits.
Exclusion Criteria
- •Prior cardiac catheter ablation for the treatment of arrhythmia within 4 months.
- •Patients who refuse, but have not failed and can tolerate anti-arrhythmic medications
- •Myocardial infarction within 8 weeks.
- •Prior cardiac surgery.
- •Patient requires cardiac surgery for treatment other than for AF.
- •Class IV NYHA heart failure symptoms, unless due to uncontrolled AF
- •Cerebrovascular accident within previous 6 months
- •Known carotid artery stenosis greater than 80%
- •Evidence of significant active infection
- •Patient unable to undergo TEE
Outcomes
Primary Outcomes
Feasibility of performing the operation by demonstrating the ability to consistently isolate the left and right pulmonary veins and to confirm conduction block across the roof, anterior and LAA linear lesions.
The primary safety endpoint will be determined by assessing the rate of serious adverse events.
Similar Trials
Completed
Not Applicable
LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of StrokeAtrial FibrillationStrokeSystemic EmbolismNCT02478294The First Affiliated Hospital with Nanjing Medical University474
Unknown
Phase 2
Sole-Therapy Treatment of Atrial FibrillationAtrial FibrillationNCT00566176AtriCure, Inc.25
Completed
Not Applicable
Study of Intra-Cardiac Echocardiography in Guiding Left Atrial Appendage Occlusion With the Watchman DeviceLeft Atrial Appendage OcclusionNCT05136417Mayo Clinic100
Recruiting
Not Applicable
Left Atrial Appendage Closure in Combination With Catheter AblationAtrial FibrillationNCT03788941Xinhua Hospital, Shanghai Jiao Tong University School of Medicine1,200
Completed
Not Applicable
The ICE WATCHMAN TrialLeft Atrial Appendage Closure With WATCHMAN Device Utilizing an Intra-procedural ICE ProbeNCT04569734Mayo Clinic101